Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93

[1]  H. Gadner,et al.  Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia. , 2000, Blood.

[2]  G. Henze,et al.  Definition of a standard‐risk group in children with AML , 1999, British journal of haematology.

[3]  T. H. A. C. O. G. Roup.  A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia , 1998 .

[4]  R. Peto,et al.  A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia , 1998, British journal of haematology.

[5]  H. Sather,et al.  Early response to therapy and outcome in childhood acute lymphoblastic leukemia , 1997, Cancer.

[6]  E. Berman.  A review of idarubicin in acute leukemia. , 1993, Oncology.

[7]  J. Ritter,et al.  Does cranial irradiation reduce the risk for bone marrow relapse in acute myelogenous leukemia? Unexpected results of the Childhood Acute Myelogenous Leukemia Study BFM-87. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  A. Bartolucci,et al.  A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  E. Berman,et al.  Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells. , 1992, Blood.

[10]  H. Gralnick,et al.  Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML‐MO) , 1991, British journal of haematology.

[11]  Janice Gabrilove,et al.  Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia , 1991 .

[12]  D. Faulds,et al.  Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer. , 1991, Drugs.

[13]  C. Bloomfield,et al.  Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  A. Carella,et al.  Idarubicin in the treatment of acute leukemias. An overview of preclinical and clinical studies. , 1990, Haematologica.

[15]  A Ward,et al.  Pentoxifylline , 1987, Drugs.

[16]  G Flandrin,et al.  Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. , 1985, Annals of internal medicine.

[17]  D. Catovsky,et al.  Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). A report of the French-American-British Cooperative Group. , 1985, Annals of internal medicine.

[18]  B. Leyland-Jones,et al.  Phase I and II clinical and pharmacological study of 4-demethoxydaunorubicin (idarubicin) in adult patients with acute leukemia. , 1985, Cancer research.

[19]  M. Adamcová,et al.  Anthracycline-induced cardiotoxicity. , 2000, Acta medica.

[20]  P. Ritch,et al.  Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. , 1992, Blood.

[21]  D. Faulds,et al.  Idarubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer. , 1991, Drugs.